FDA OKs Risankizumab for Crohn's Disease

Approval marks the third indication for the IL-23 inhibitor in adults

Related Keywords

New York ,United States ,Chicago ,Illinois ,Zaina Hamza ,Marla Dubinsky ,Icahn School Of Medicine At Mount Sinai ,Icahn School ,Mount Sinai ,New York City ,Disease Activity Index ,Simple Endoscopic Score ,Medpage Today ,